TABLE 1.
Vaccine Response According to DMT
| Serostatus following dose 1 (positive:negative, % seroconverted) | Serostatus following dose 2 (positive:negative, % seroconverted) | OR seroconversion following dose 2 (OR; 95% CI) | Proportion seroconverted post‐ ChAdOx1 nCoV‐19 (Oxford‐AZ) vaccine (positive:negative, % seroconverted) a | Proportion seroconverted post‐ BNT162b2 (Pfizer) vaccine (positive:negative, % seroconverted) b | |
|---|---|---|---|---|---|
| All participants | 140:106 (57%) | 280:150 (65%) | NA | 107:80 (57%) c | 113:37 (75%) c |
| No DMT | 77:18 (81%) | 85:7 (92%) | 1 (reference) | 27:2 (93%) | 41:0 (100%) |
| Anti‐CD20 mAb d | 7:45 (13%) | 33:101 (25%) | 0.03 (0.01–0.06) e | 16:57 (22%) | 11:24 (31%) |
| Natalizumab | 23:8 (74%) | 56:5 (92%) | 0.92 (0.28–3.05) | 28:2 (93%) | 25:2 (93%) |
| Alemtuzumab | 14:4 (78%) | 24:4 (86%) | 0.49 (0.13–1.83) | 14:3 (82%) | 9:1 (90%) |
| Dimethyl fumarate | 9:7 (56%) | 35:3 (92%) | 0.96 (0.23–3.93) | 12:3 (80%) | 14:0 (100%) |
| Cladribine | 1:7 (13%) | 16:4 (80%) | 0.33 (0.09–1.26) | 5:3 (63%) | 9:1 (90%) |
| Glatiramer acetate | 2:0 (100%) | 3:0 (100%) | NA f | NA g | NA g |
| Fingolimod | 4:15 (21%) | 12:24 (33%) | 0.04 (0.01–0.12) e | 5:10 (33%) | 4:9 (31%) |
| Interferon beta | 3:0 (100%) | 5:1 (83%) | 0.41 (0.04–4.03) | NA g | NA g |
| Teriflunomide | 0:2 (0%) | 3:0 (100%) | NA f | NA g | NA g |
| p < 0.0001 | p < 0.0001 |
Total n = 187 with samples following vaccine 2 and vaccine type available.
Total n = 150 with samples following vaccine 2 and vaccine type available.
Direct comparison not performed as groups not equivalent; subgroup comparisons subject to multiple testing concerns and therefore not performed.
Ocrelizumab, rituximab, and ofatumumab.
The p < 0.0001 using Univariate logistic regression with no DMT as the reference group was used across DMT groups to provide odds ratio of seroconversion by DMT class.
Logistic regression limited by small numbers.
Data not presented as interpretation limited by small numbers.
AZ = Astra Zeneca; CI = confidence interval; DMT = disease modifying therapy; mAb = monoclonal antibody; NA = not applicable; nCoV = novel coronavirus; OR = odds ratio.